|
Symbol Name ID |
Rarres1
retinoic acid receptor responder (tazarotene induced) 1 MGI:1924461 |
| Allelic Composition Genetic Background |
Annotated Term | Reference |
| Rarres1tm1.2Mhl/Rarres1+ involves: 129S1/SvImJ * C57BL/6 * FVB/N * NIH Black Swiss |
increased follicular lymphoma incidence | J:324270 |
| Rarres1tm1.2Mhl/Rarres1tm1.2Mhl involves: 129S1/SvImJ * C57BL/6 * FVB/N * NIH Black Swiss |
abnormal B cell activation | J:324270 |
| abnormal B cell differentiation | J:324270 | |
| abnormal B cell physiology | J:324270 | |
| abnormal cell physiology | J:324270 | |
| abnormal plasma cell differentiation | J:324270 | |
| decreased B cell apoptosis | J:324270 | |
| decreased spleen germinal center number | J:324270 | |
| extramedullary hematopoiesis | J:324270 | |
| increased B cell proliferation | J:324270 | |
| increased follicular lymphoma incidence | J:324270 | |
| Rarres1tm1d(KOMP)Wtsi/Rarres1+ involves: C57BL/6N |
increased follicular lymphoma incidence | J:324270 |
| Rarres1tm1d(KOMP)Wtsi/Rarres1tm1d(KOMP)Wtsi involves: C57BL/6N |
neonatal lethality, complete penetrance | J:324270 |
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 10/07/2025 MGI 6.24 |
|
|
|
||